Of the 418 patients treated with Caelyx 50 mg/ m2/ cycle, and having a baseline measurement of left ventricular ejection fraction (LVEF) and at least one follow-up measurement assessed by MUGA scan, 88 patients had a cumulative anthracycline dose of > 400 mg/ m2, an exposure level associated with an increased risk of cardiovascular toxicity with conventional doxorubicin.